VIDEO: Study investigates novel therapy for penetration of pediatric brain tumors

ByCassie Kline, MD, MAS

ByGeorgia I Salvaryn

Fact checked byMindy Valcarcel, MS

Add topic to email alerts

Please provide your email address to receive an email when new articles are posted on Pediatric Oncology.

PHILADELPHIA — In this video, Cassie Kline, MD, MAS, discusses the results of the PNOC016 trial she presented at International Symposium on Pediatric Neuro-Oncology.

The study observed the intratumoral pharmacokinetics and pharmacodynamic results of fimepinostat (Curis) in treating high-risk brain tumors in children and young adults with newly diagnosed diffuse intrinsic pontine gliomas, recurrent medulloblastoma or recurrent high-grade gliomas.

“[These] novel clinical trials [explore] not just the impact of drug on survival but [look] at intratumoral drug penetration and pharmacodynamic markers of response and [present] on ways in which we should be thinking about trial design and how we are answering or addressing questions of ‘how’ or ‘why’ a drug is working,” Kline, a pediatric neuro-oncology attending and director of neuro-oncology clinical research at Children’s Hospital of Philadelphia, said.

Reference:

Kline C, et al. Abstract TRLS-07. Presented at: International Symposium on Pediatric Neuro-Oncology; June 28-July 2, 2024; Philadelphia.

Published by:

Sources/Disclosures

Collapse

Disclosures: Kline reports grants from and/or clinical trial contracts with Bristol Myers Squibb, Cannonball Kids’ cancer Foundation, Chimerix, Curis, Day One Biopharmaceuticals, Ipsen, Kazia Therapeutics, Kortney Rose Foundation, Midatech Pharma and Regeneron Pharmaceuticals.